HRT+HEP – The perfect couple for a reliable glaucoma diagnosis

Article

Heidelberg Engineering is a high-tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. It is a privately held company, headquartered in Heidelberg, Germany.

Heidelberg Engineering complements the gold standard of structural glaucoma diagnosis, the Heidelberg Retina Tomograph (HRT) with an innovative and reliable partner, the Heidelberg Edge Perimeter (HEP).

The HRT is a confocal laser scanning ophthalmoscope designed for the examination of the eye’s posterior pole. The integrated Moorfields Regression Analysis (MRA) classifies the optic nerve head (ONH) into healthy or glaucomatous by detecting diffuse and focal changes of the neuroretinal rim area.

Evaluating the central visual field, the HEP is designed for the use in early glaucoma detection as well as in progression analysis. The multi-functional HEP uses two different stimuli in one perimeter: the unique Flicker-Defined-Form (FDF) stimulus that creates an illusory “edge” contour and the well-known Standard Automated white-on-white Perimetry (SAP), that is useful in patients with moderate to severe disease and for continuity of care.

The new approach of HEP to visual fields was designed to work in combination with the well-established HRT. The Structure-Function Map (SF Map), a single report, is a combination of the HRT’s ability to classify significant change of the ONH and conjointly displays the given structural information with the functional information of the visual field.

http://www.heidelbergengineering.com/international/products/hep/structure-and-function-together-at-last/

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.